CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
319.54
0.71%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.39
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024901 %
Charges from full value of position ($-4.73)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024901%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002679 %
Charges from full value of position ($0.51)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002679%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.35
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 317.28
Open 317.71
1-Year Change 21.78%
Day's Range 316.56 - 320.09
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 4, 2024 319.54 1.96 0.62% 317.58 320.57 316.02
Oct 3, 2024 317.28 0.83 0.26% 316.45 319.48 315.35
Oct 2, 2024 319.47 1.69 0.53% 317.78 320.44 316.22
Oct 1, 2024 320.11 -0.38 -0.12% 320.49 321.90 316.80
Sep 30, 2024 321.99 1.04 0.32% 320.95 322.95 318.43
Sep 27, 2024 322.47 0.57 0.18% 321.90 327.73 320.45
Sep 26, 2024 318.79 5.09 1.62% 313.70 319.58 312.95
Sep 25, 2024 312.63 -15.57 -4.74% 328.20 328.55 312.01
Sep 24, 2024 330.85 -2.10 -0.63% 332.95 335.20 330.37
Sep 23, 2024 335.43 -3.02 -0.89% 338.45 338.92 333.00
Sep 20, 2024 337.23 2.18 0.65% 335.05 338.86 333.70
Sep 19, 2024 335.89 -0.82 -0.24% 336.71 338.49 334.55
Sep 18, 2024 332.64 -0.59 -0.18% 333.23 338.68 329.99
Sep 17, 2024 332.75 -0.56 -0.17% 333.31 334.19 330.95
Sep 16, 2024 335.20 0.79 0.24% 334.41 337.28 332.71
Sep 13, 2024 332.30 5.71 1.75% 326.59 334.26 326.59
Sep 12, 2024 329.98 0.29 0.09% 329.69 331.89 326.22
Sep 11, 2024 329.64 2.09 0.64% 327.55 330.54 320.23
Sep 10, 2024 328.74 2.29 0.70% 326.45 329.13 322.27
Sep 9, 2024 325.75 3.48 1.08% 322.27 327.64 320.04

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Amgen Company profile

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).

Equity composition

Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).

Industry: Pharmaceuticals (NEC)

One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US

News

September US Non-Farm Payrolls Preview

Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.

07:59, 2 October 2024

Market of the Month - Gold, an overview

In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.

06:00, 30 September 2024

RBA Preview: Rates to remain unchanged with inflation-fighting still the focus

RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.

12:27, 20 September 2024

BoE Preview: no change expected but forward guidance will be key

The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.

14:53, 19 September 2024

FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion

Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.

11:30, 19 September 2024

Bank of Japan Preview

The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.

09:40, 17 September 2024

FOMC Decision Preview

As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.

09:48, 16 September 2024

People also watch

BTC/USD

62,248.00 Price
-0.370% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

20,006.40 Price
+1.220% 1D Chg, %
Long position overnight fee -0.0249%
Short position overnight fee 0.0027%
Overnight fee time 21:00 (UTC)
Spread 7.0

Oil - Crude

74.16 Price
+0.940% 1D Chg, %
Long position overnight fee 0.0143%
Short position overnight fee -0.0362%
Overnight fee time 21:00 (UTC)
Spread 0.040

Gold

2,653.71 Price
-0.100% 1D Chg, %
Long position overnight fee -0.0178%
Short position overnight fee 0.0096%
Overnight fee time 21:00 (UTC)
Spread 0.60

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading